Valuation dashboard for Dyne Therapeutics, Inc. (DYN) with P/E N/A, P/B 4.08, EV/EBITDA -5.2 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At $17.30 (closing price, November 2, 2026), DYN has negative trailing earnings (P/E not meaningful) and an ROE of -64.30%. Market capitalisation stands at $3.2B.
Balance sheet quality for DYN: debt-to-equity ratio of 0.03, current ratio of 12.02 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 4.08 |
| EV / EBITDA | -5.2 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| DYN | Dyne Therapeutics, Inc. | $3.2B | 4.08 | -64.3% | |
| IONS | Ionis Pharmaceuticals, Inc. | $6.9B | 15.51 | -110.8% | |
| PTCT | PTC Therapeutics, Inc. | $5.1B | 57.1% | ||
| VRTX | Vertex Pharmaceuticals Incorporated | $140.2B | 35.60 | 4.28 | 17.5% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| REGN | Regeneron Pharmaceuticals, Inc. | $99.0B | 21.24 | 2.92 | 15.1% |
| MRNA | Moderna, Inc. | $88.2B | 12.93 | -39.2% | |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
Price
| Price | $17.30 (closing price, November 2, 2026) |
| Market Cap | $3.2B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -64.30% |
| Return on Invested Capital | -58.28% |
| Return on Assets | -52.25% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: IONS · PTCT · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of DYN: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks